Early clinical studies of CAR T cells for AML are ongoing, exploring several targets including CD123 (9, 10), CD33 (11), C-type lectin-like molecule 1 (CLL-1) (12, 13), and Lewis-Y (14). This evidence concerns the gene CD33 and acute myeloid leukemia.